Laden…
3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
Remoxipride is an atypical antipsychotic from the class of benzamides, primarily acting as a dopamine D2 receptor antagonist. It has been used for the treatment of schizophrenia and is characterized by selective inhibition of dopamine D2 receptors. Due to side effects such as seizures, its clinical use has been restricted. The substance primarily affects dopaminergic signaling pathways and exhibits a moderate side effect profile.
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Designations
IUPAC: 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Total duration 12-24 hours
Peak
2-4 hours
Onset
1-2 hours
Total duration
12-24 hours
After effects
Variable
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Sedierung, Gewichtszunahme und extrapyramidale Symptome.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.